NICE

Nice (NICE) reached $115.02 at the closing of the latest trading day, reflecting a -2.1% change compared to its last close.

Zacks.com users have recently been watching Nice (NICE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Company Recognized for Connecting Public Sector Organizations With AI-Powered Customer Service Solutions Company Recognized for Connecting Public Sector Organizations With AI-Powered Customer Service Solutions

CAMBRIDGE, England--(BUSINESS WIRE)--FOR UK HEALTHCARE/TRADE MEDIA ONLY Sobi® UK today announced that the National Institute for Health and Care Excellence (NICE) has issued final draft guidance which recommends Tryngolza® (olezarsen) as an option to treat genetically confirmed familial chylomicronaemia syndrome (FCS) in adults in England and Wales, only if response to diet and conventional triglyceride-lowering treatments (such as statins and fibrates) has been inadequate. FCS is an ultra-rare.

NICE Ltd. remains a Buy, with AI-driven growth and a low valuation underpinning the investment thesis. AI and Self-Service ARR surged 52% year-over-year, now 15% of cloud revenue, signaling robust demand and platform relevance. Margin compression persists as NICE invests in AI and expansion, but strong cash flow and buybacks provide downside protection.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Nice (NICE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Nice (NICE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Artisan International Small-Mid Fund portfolio modestly trailed the MSCI ACWI ex USA SMID Index in Q2. On an individual company basis, NICE, Landis+Gyr and DBV Technologies were the largest Q2 detractors. Our top contributors for the quarter were Rohm, LivaNova and Glanbia.